SIU 2017: UP21 - Usefulness of Laparoscopic Partial Adrenalectomy: Single Surgeon Experience

Lisbon, Portugal (UroToday.com) There is growing interest in partial adrenalectomy to avoid the side effects of potential adrenal insufficiency and life-long steroid replacement in select cases. Therefore, the authors presented a study evaluating the usefulness of laparoscopic partial adrenalectomy (LPA) by comparing the surgical and long-term functional results of LPA to those of laparoscopic total adrenalectomy (LTA).
Read more ...

 SIU 2017: UP17 - Carcinoma of the Collecting Ducts of Bellini - Clinicopathological Features

Lisbon, Portugal (UroToday.com) Carcinoma of the collecting ducts of Bellini (CDC) is a rare disease, thought to be derived from the cells of the collecting duct of Bellini and accounts for <1% of renal malignancies. The rarity of these tumours and heterogeneity of histopathologic features, which occasionally overlap with papillary renal cell carcinoma, and urothelial carcinoma of the kidney, limit our understanding of it. Optimal management of CDC is lacking. The authors therefore aimed to investigate the clinicopathologic features of CDC.
Read more ...

SIU 2017: UP15 - Current Diagnostic Accuracy of Conventional Computed Tomography Scan in Surgically Removed Benign Renal Tumors

Lisbon, Portugal (UroToday.com) There is a growing need to improve the accuracy of diagnosing benign renal tumors preoperatively, as it would reduce subsequent unnecessary invasive treatments. In this study, the authors evaluated the current accuracy of computed tomography (CT) for diagnosing benign renal tumors.
Read more ...

SIU 2017: Predicting Tumour Recurrence in Patients Treated with Bacillus Calmette-Guérin

Lisbon, Portugal (UroToday.com0 In this study, the authors attempt to use a urine based biomarker test to better identify BCG failures – they state that there is no good test to assess BCG failure at this time, thought TURBT remains the standard. They assess whether UroVysion FISH can identify early BCG failure, perhaps earlier than TURBT.
Read more ...

SIU 2017: Red Patches Seen during Endoscopic Surveillance of Bladder Cancer – When Should we Biopsy?

Lisbon, Portugal (UroToday.com) “Red patches” are a common finding on surveillance or initial cystoscopy that urologists are often concerned represent carcinoma-in-situ (CIS). However, bladder irritation, infection, or scope trauma can cause similar findings. 

In this study, the group from the UK retrospectively reviewed the charts of 4805 flexible cystoscopy reports over a 12 month period for the finding of “red patch.” Not every patient with the finding of “red patch” went on to biopsy, but they evaluate those that did.
Read more ...

SIU 2017: Factors Predicting Concomitant Carcinoma in Situ in Patients with Initially Diagnosed Non-Muscle Invasive Bladder Cancer

Lisbon, Portugal (UroToday.com) In this study, the authors assess the role of random bladder biopsies. While recent guidelines have already indicated the role of random bladder biopsies (typically in setting of positive cytology but negative cystoscopy, or in consideration of partial cystectomy), the authors complete a single institution assessment of predictors of positive bladder biopsies. 
Read more ...

SIU 2017: Results of Repeat Transurethral Resection of Bladder Tumor (TURBT) by Institution Performing the Initial TURBT: Comparative Analyses between Referred and Non-Referred Group

Lisbon, Portugal (UroToday.com) Repeat TURBT after an initial diagnosis of NMIBC, specifically high-grade T1 disease, is recommended by most guidelines. Due to moderate ~20-30% rate of understaging on initial TURBT, repeat TURBT is recommended to ensure that MIBC is not missed. However, considering the potential cost implications, patient discomfort, and potential risks of repeat TURBT, there has been renewed interest to reassess the need of repeat TURBT.
Read more ...